52 related articles for article (PubMed ID: 21492162)
1. A modified Tat peptide for selective intracellular delivery of macromolecules.
Murphy DJ; Walker B; Greer B; Harriott P; Martin SL
J Pharm Pharmacol; 2011 May; 63(5):611-8. PubMed ID: 21492162
[TBL] [Abstract][Full Text] [Related]
2. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
3. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
4. Tat(48-60) peptide amino acid sequence is not unique in its cell penetrating properties and cell-surface glycosaminoglycans inhibit its cellular uptake.
Subrizi A; Tuominen E; Bunker A; Róg T; Antopolsky M; Urtti A
J Control Release; 2012 Mar; 158(2):277-85. PubMed ID: 22100438
[TBL] [Abstract][Full Text] [Related]
5. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
6. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
7. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
[TBL] [Abstract][Full Text] [Related]
8. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Liang OD; Chavakis T; Linder M; Bdeir K; Kuo A; Preissner KT
Biol Chem; 2003 Feb; 384(2):229-36. PubMed ID: 12675515
[TBL] [Abstract][Full Text] [Related]
9. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
10. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a near-infrared fluorescent nanofiber precursor for detecting cell-secreted urokinase activity.
Malik R; Qian S; Law B
Anal Biochem; 2011 May; 412(1):26-33. PubMed ID: 21237128
[TBL] [Abstract][Full Text] [Related]
12. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence.
Ziegler A; Nervi P; Dürrenberger M; Seelig J
Biochemistry; 2005 Jan; 44(1):138-48. PubMed ID: 15628854
[TBL] [Abstract][Full Text] [Related]
13. Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin.
Chen LL; Frankel AD; Harder JL; Fawell S; Barsoum J; Pepinsky B
Anal Biochem; 1995 May; 227(1):168-75. PubMed ID: 7668378
[TBL] [Abstract][Full Text] [Related]
14. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells.
Wickström SA; Veikkola T; Rehn M; Pihlajaniemi T; Alitalo K; Keski-Oja J
Cancer Res; 2001 Sep; 61(17):6511-6. PubMed ID: 11522648
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
16. Expression and activation of proteases in co-cultures.
Paduch R; Kandefer-Szerszeń M
Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
[TBL] [Abstract][Full Text] [Related]
17. Effective antibacterial action of tat (47-58) by increased uptake into bacterial cells in the presence of trypsin.
Jung HJ; Jeong KS; Lee DG
J Microbiol Biotechnol; 2008 May; 18(5):990-6. PubMed ID: 18633303
[TBL] [Abstract][Full Text] [Related]
18. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]